SDGR (43) AGIO (39) PRGO (41) AUPH (75) ⌘ Pro Terminal →

Harmony Biosciences Holdings Inc. (HRMY) — RQD Stock Rating Cockpit

$38.59 +0.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of B+ (Buy) with 80/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HRMY)Realized 20D OHLCV Swing Band: ±8.9%

RSI-14 MOMENTUMNEUTRAL RANGE

51.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

5.38>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

9 / 99-Pt Accounting

52-WEEK LASER RANGE72% OF RANGE

L: $26$38.59H: $43

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (77% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 20 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 33 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on HRMY

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (98)

63.0% ROIC with 77.2% gross margin and 15.48% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 5.38 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (70)

27/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like HRMY

✓Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (HRMY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HRMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.45%📐 HORIZONTAL RANGE

2026-10-30O $38.58H $39.10L $38.39C $38.59VOL 871.3K

RES: $47.87SUP: $33.63SMA50: $39.76SMA200: $34.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HRMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HRMY Butterfly Map → + Track HRMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

6.0%/yr Implied 5Y Growth

vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HRMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HRMY)

Health Care Rank #18 of 1016 ⚔️ SDGR vs HRMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HRMY vs. SDGR, AGIO, PRGO, AUPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #18 by composite RQD confidence (80/100, grade B+) and #239 by equity capitalization ($2.25B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 80/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HRMY ACTIVE Harmony Biosciences Holdings Inc.	B+	80/100	14.2x	77.2%	63.0%	+0.23%	$2.25B	Benchmark Subject
SDGR Schrodinger Inc.	D-	43/100	—	55.7%	-35.0%	-2.85%	$2.24B	/sdgr-vs-hrmy →
AGIO Agios Pharmaceuticals Inc.	D-	39/100	—	88.3%	-33.8%	-2.33%	$2.22B	/agio-vs-hrmy →
PRGO Perrigo Company plc	D-	41/100	—	35.1%	-13.6%	-0.13%	$2.21B	/prgo-vs-hrmy →
AUPH Aurinia Pharmaceuticals Inc	B	75/100	8.0x	88.5%	16.5%	-0.86%	$2.29B	/auph-vs-hrmy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802665

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$868.5M	$158.7M	$348.2M	$347.9M	$1.27B	$143.7M
FY2024 (FY)	2024-12-31	$714.7M	$145.5M	$219.8M	$218.7M	$999.2M	$163.0M
FY2023 (FY)	2023-12-31	$582.0M	$128.9M	$219.4M	$219.4M	—	—

3. HRMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $38.59 (+0.23% 1D, market cap $2.25B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #18 in composite RQD confidence.

How does HRMY compare to SDGR and AGIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable B+ (80/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, SDGR (Schrodinger Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.24B) and AGIO (Agios Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.8%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HRMY?

Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HRMY trading relative to its 50-day, 200-day, and 52-week technical levels?

HRMY last traded at $38.59 (+0.23% on volume of 778,885 shares), positioning the stock -2.94% below its 50-day simple moving average ($39.76) and +11.24% above its 200-day simple moving average ($34.69). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 72.1% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($35.16 to $42.02).

HRMY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HRMY stock right now?

Harmony Biosciences Holdings Inc. (HRMY) currently earns a Roarable Rating of B+ (Buy — BUY) with 80/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support.

What is HRMY's 12-month price target and RQD AI Jury consensus?

HRMY's 12-month base price target is $42.41 (range $31.64 to $50.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HRMY RQD Cockpit HRMY 12M Forecast HRMY Earnings & Move HRMY Dividends & DRIP HRMY Insiders & 13F HRMY Whale Options HRMY Profit Sankey HRMY News & Why